» Articles » PMID: 2050110

Endocytosis and Targeting of Exogenous HIV-1 Tat Protein

Overview
Journal EMBO J
Date 1991 Jul 1
PMID 2050110
Citations 133
Authors
Affiliations
Soon will be listed here.
Abstract

The human immunodeficiency virus-1 (HIV-1) Tat protein has previously been shown to transactivate the HIV-1-LTR when added exogenously to HeLa, H9 lymphocytic and U937 promonocytic cells growing in culture. Here we show that Tat enters these cells by adsorptive endocytosis. Tat appears to bind non-specifically to the cell surface, with greater than 10(7) sites per cell. A specific receptor was not detected by protein crosslinking experiments, and uptake was not affected by treating cells with trypsin, heparinase or neuraminidase. Uptake and transactivation could be inhibited by incubation with heparin, dextran sulfate, an anti-Tat monoclonal antibody, or by incubation at 4 degrees C. In contrast, transactivation by Tat was markedly stimulated by the addition of basic peptides, such as Tat 38-58 or protamine. Fluorescence experiments with rhodamine-conjugated Tat show punctate staining on the cell surface and then localization to the cytoplasm and nucleus. The lack of a specific receptor makes it unclear whether Tat uptake is biologically important in HIV infection, however, the efficiency of uptake raises the possibility that Tat may be useful for delivery of protein molecules into cells.

Citing Articles

Towards Cell-Permeable Hepatitis B Virus Core Protein Variants as Potential Antiviral Agents.

Bendahmane S, Follo M, Zhang F, Linhardt R Microorganisms. 2024; 12(9).

PMID: 39338451 PMC: 11434381. DOI: 10.3390/microorganisms12091776.


ER Stress and Mitochondrial Perturbations Regulate Cell Death in Retinal Detachment: Exploring the Role of HIF1α.

Kaur B, Scavuzzi B, Yang M, Yao J, Jia L, Abcouwer S Invest Ophthalmol Vis Sci. 2024; 65(11):39.

PMID: 39325470 PMC: 11437674. DOI: 10.1167/iovs.65.11.39.


Amphipathic Cell-Penetrating Peptide-Aided Delivery of Cas9 RNP for In Vitro Gene Editing and Correction.

Oktem M, Mastrobattista E, de Jong O Pharmaceutics. 2023; 15(10).

PMID: 37896260 PMC: 10609989. DOI: 10.3390/pharmaceutics15102500.


Strategies for overcoming protein and peptide instability in biodegradable drug delivery systems.

Shi M, McHugh K Adv Drug Deliv Rev. 2023; 199:114904.

PMID: 37263542 PMC: 10526705. DOI: 10.1016/j.addr.2023.114904.


Peptides for trans-blood-brain barrier delivery.

Blades R, Ittner L, Tietz O J Labelled Comp Radiopharm. 2023; 66(9):237-248.

PMID: 37002811 PMC: 10952576. DOI: 10.1002/jlcr.4023.


References
1.
Cullen B . Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism. Cell. 1986; 46(7):973-82. DOI: 10.1016/0092-8674(86)90696-3. View

2.
Fisher A, Feinberg M, Josephs S, Harper M, Marselle L, Reyes G . The trans-activator gene of HTLV-III is essential for virus replication. Nature. 1986; 320(6060):367-71. DOI: 10.1038/320367a0. View

3.
HAUBER J, Perkins A, Heimer E, Cullen B . Trans-activation of human immunodeficiency virus gene expression is mediated by nuclear events. Proc Natl Acad Sci U S A. 1987; 84(18):6364-8. PMC: 299076. DOI: 10.1073/pnas.84.18.6364. View

4.
Nevins J . Isolation and analysis of nuclear RNA. Methods Enzymol. 1987; 152:234-41. DOI: 10.1016/0076-6879(87)52025-0. View

5.
Felber B, Pavlakis G . A quantitative bioassay for HIV-1 based on trans-activation. Science. 1988; 239(4836):184-7. DOI: 10.1126/science.3422113. View